Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments

Major limitations of current melanoma treatments are for instances of relapse and the lack of therapeutic options for BRAF wild-type patients who do not respond to immunotherapy. Many studies therefore focus on killing resistant subpopulations, such as Melanoma Initiating Cells (MICs) to prevent rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Nabanita, Almeida, Adam, Partyka, Katie A., Lu, Yan, Schwan, Josianna V., Lambert, Karoline, Rogers, Madison, Robinson, William A, Robinson, Steven E, Applegate, Allison J, Amato, Carol M, Luo, Yuchun, Fujita, Mayumi, Norris, David A., Shellman, Yiqun G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356684/
https://www.ncbi.nlm.nih.gov/pubmed/27829238
http://dx.doi.org/10.18632/oncotarget.13141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356684/
https://www.ncbi.nlm.nih.gov/pubmed/27829238
http://dx.doi.org/10.18632/oncotarget.13141

Ejemplares similares